1. Home
  2. ICCC vs AIXI Comparison

ICCC vs AIXI Comparison

Compare ICCC & AIXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICCC
  • AIXI
  • Stock Information
  • Founded
  • ICCC 1982
  • AIXI 2001
  • Country
  • ICCC United States
  • AIXI China
  • Employees
  • ICCC N/A
  • AIXI N/A
  • Industry
  • ICCC Biotechnology: Pharmaceutical Preparations
  • AIXI Computer Software: Prepackaged Software
  • Sector
  • ICCC Health Care
  • AIXI Technology
  • Exchange
  • ICCC Nasdaq
  • AIXI Nasdaq
  • Market Cap
  • ICCC 45.9M
  • AIXI 54.2M
  • IPO Year
  • ICCC 1987
  • AIXI 2023
  • Fundamental
  • Price
  • ICCC $5.11
  • AIXI $5.19
  • Analyst Decision
  • ICCC
  • AIXI
  • Analyst Count
  • ICCC 0
  • AIXI 0
  • Target Price
  • ICCC N/A
  • AIXI N/A
  • AVG Volume (30 Days)
  • ICCC 10.1K
  • AIXI 111.3K
  • Earning Date
  • ICCC 02-25-2025
  • AIXI 10-28-2024
  • Dividend Yield
  • ICCC N/A
  • AIXI N/A
  • EPS Growth
  • ICCC N/A
  • AIXI N/A
  • EPS
  • ICCC N/A
  • AIXI N/A
  • Revenue
  • ICCC $23,838,001.00
  • AIXI $65,643,604.00
  • Revenue This Year
  • ICCC N/A
  • AIXI $22.85
  • Revenue Next Year
  • ICCC N/A
  • AIXI $22.70
  • P/E Ratio
  • ICCC N/A
  • AIXI N/A
  • Revenue Growth
  • ICCC 46.37
  • AIXI 6.22
  • 52 Week Low
  • ICCC $3.34
  • AIXI $2.06
  • 52 Week High
  • ICCC $5.82
  • AIXI $22.05
  • Technical
  • Relative Strength Index (RSI)
  • ICCC 52.70
  • AIXI 45.21
  • Support Level
  • ICCC $4.86
  • AIXI $5.03
  • Resistance Level
  • ICCC $5.50
  • AIXI $5.86
  • Average True Range (ATR)
  • ICCC 0.36
  • AIXI 0.49
  • MACD
  • ICCC -0.03
  • AIXI -0.02
  • Stochastic Oscillator
  • ICCC 39.06
  • AIXI 15.97

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

About AIXI XIAO-I Corporation

XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.

Share on Social Networks: